Literature DB >> 16906565

Expanding the clinical spectrum of MYCN-related Feingold syndrome.

Alexandra Tészás, Rowdy Meijer, Hans Scheffer, Petra Gyuris, György Kosztolányi, Hans van Bokhoven, Richard Kellermayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16906565     DOI： 10.1002/ajmg.a.31407

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN： 1552-4825            Impact factor:   2.802


× No keyword cloud information.
  6 in total

1.  A Novel MYCN Variant Associated with Intellectual Disability Regulates Neuronal Development.

Authors:  Xiuya Yu; Liyuan Hu; Xu Liu; Guodong Zhan; Mei Mei; Huijun Wang; Xiaohua Zhang; Zilong Qiu; Wenhao Zhou; Lin Yang
Journal:  Neurosci Bull       Date:  2018-05-21       Impact factor: 5.203

2.  Neurobehavioral Alterations in a Genetic Murine Model of Feingold Syndrome 2.

Authors:  E Fiori; L Babicola; D Andolina; A Coassin; T Pascucci; L Patella; Y-C Han; A Ventura; R Ventura
Journal:  Behav Genet       Date:  2015-05-31       Impact factor: 2.805

3.  A new variant of MYCN gene as a cause of Feingold syndrome.

Authors:  Naim Zeka; Ramush Bejiqi; Abdurrahim Gerguri; Leonore Zogaj; Haki Jashari
Journal:  Clin Case Rep       Date:  2022-05-23

4.  c-myc and N-myc promote active stem cell metabolism and cycling as architects of the developing brain.

Authors:  Alice Wey; Paul S Knoepfler
Journal:  Oncotarget       Date:  2010-06

5.  c- and N-myc regulate neural precursor cell fate, cell cycle, and metabolism to direct cerebellar development.

Authors:  Alice Wey; Veronica Martinez Cerdeno; David Pleasure; Paul S Knoepfler
Journal:  Cerebellum       Date:  2010-12       Impact factor: 3.847

6.  Prenatal detection of chromosomal abnormalities and copy number variants in fetuses with congenital gastrointestinal obstruction.

Authors:  Xinyue Meng; Lili Jiang
Journal:  BMC Pregnancy Childbirth       Date:  2022-01-19       Impact factor: 3.007
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.